Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
224 hedge funds and large institutions have $2.54B invested in Sage Therapeutics in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 72 increasing their positions, 76 reducing their positions, and 18 closing their positions.
72% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 18
30% more call options, than puts
Call options by funds: $21.6M | Put options by funds: $16.6M
14% more capital invested
Capital invested by funds: $2.22B → $2.54B (+$321M)
6% more funds holding
Funds holding: 212 → 224 (+12)
1.99% more ownership
Funds ownership: 88.53% → 90.53% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 76
Top Buyers
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$41.2M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$30.5M |
| 3 |
BlackRock
New York
|
-$25.2M |
| 4 |
State Street
Boston,
Massachusetts
|
-$21.7M |
| 5 |
Goldman Sachs
New York
|
-$21.6M |
SAGE Hedge Fund Activity: Q2 2023 in Review
224 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2023, worth a combined $2.54B — up 14% from $2.22B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new SAGE positions and 18 closed out — a net gain of 13 holders — while 72 added to existing stakes and 76 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $84.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $41.2M.
- 224 institutional investors held Sage Therapeutics (SAGE) as of Q2 2023, up from 212 in Q1 2023.
- Funds reported $2.54B of Sage Therapeutics stock for Q2 2023, up 14% quarter-over-quarter.
- 31 funds opened new Sage Therapeutics positions in Q2 2023 and 18 closed out, a net change of +13 holders.
- The largest Sage Therapeutics buyer in Q2 2023 was Fidelity Investments, an estimated $84.9M added.
- The largest Sage Therapeutics seller in Q2 2023 was T. Rowe Price Associates, an estimated $41.2M sold.
Based on aggregated 13F filings for Q2 2023.